Viking Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) will participate in two investor conferences in November 2025.
Stifel 2025 Healthcare Conference: management will hold a fireside chat and investor meetings on Nov 11, 2025 (4:40–5:10 p.m. ET) in New York.
Jefferies 2025 Global Healthcare Conference – London: management will deliver a corporate presentation and meet investors on Nov 19, 2025 (8:00–8:25 a.m. GMT / webcast available) in London; a live webcast and replay will be available on Viking's Investors & Media Webcasts page.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VKTX gained 5.31%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.3% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $216M to the company's valuation, bringing the market cap to $4.27B at that time.
Data tracked by StockTitan Argus on the day of publication.
Details of the company's participation are as follows:
-
Stifel 2025 Healthcare Conference
Details: Viking management will participate in a fireside chat and in investor meetings
Conference Dates: November 11-13, 2025
Fireside Chat Time/Date: 4:40 – 5:10 p.m. Eastern Time on Tuesday, November 11, 2025
Location:New York, NY -
Jefferies 2025 Global Healthcare Conference –
London
Details: Viking management will deliver a corporate presentation and participate in investor meetings
Conference Dates: November 17-20, 2025
Presentation Time/Date: 8:00 – 8:25 a.m. Greenwich Mean Time (3:00 – 3:25 a.m. Eastern Time) on Wednesday, November 19, 2025, webcast available
Location:London, UK
A live webcast of the Jefferies presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302602732.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics (VKTX) present at the Stifel 2025 Healthcare Conference?
What time is the Viking Therapeutics (VKTX) Jefferies 2025 Global Healthcare presentation in London?
Will Viking Therapeutics (VKTX) webcast its Jefferies London presentation?
Where can investors find the Viking Therapeutics (VKTX) conference webcasts and replays?
Which investor events will Viking Therapeutics (VKTX) attend in November 2025?
